<DOC>
	<DOCNO>NCT03053362</DOCNO>
	<brief_summary>The purpose study evaluate sensitivity THINC-it tool , measure change cognitive deficit individual MDD receive vortioxetine . Vortioxetine use study antidepressant improve mood , cognition quality life . `` Cognition '' refers intellectual function think , understand , learn remember . Vortioxetine approve Health Canada treatment MDD . In addition , vortioxetine report beneficial effect cognitive area executive function , attention/speed processing , memory , commonly affect negatively MDD . Vortioxetine recognize Health Authorities EU many country benefit cognitive dysfunction ( loss intellectual function ) patient MDD.Cognitive dysfunction highly persistent , pervasive progressive abnormality young adult ( i.e. , 18-65 year ) MDD . It also show among adult MDD gainfully employ , measure cognition great determinant overall workplace performance total depression symptom severity . Several line evidence indicate cognitive deficit persist episode depression critical determinant functional recovery workplace . The functional implication associate cognitive impairment provide impetus systematic evaluation , measurement assessment domains cognition expect impaired patient population . To date , measurement tool sufficiently validate and/or determine sensitive cognitive deficit young adult MDD . Major limitation available comprehensive psychometric tool include relative lack availability , cost , lack access healthcare provider , else , lengthy time administer . Moreover , need psychometrist interpret result add complexity costliness endeavor . It imperative tool recommend clinical utility align busy nature high-volume clinical practice . The ideal gold standard tool assess presence cognitive dysfunction MDD clinical environment include , limited , feature good conceptual coverage cognitive domain affect MDD , good sensitivity reliability , relatively uninfluenced culture effect practice effect . The tool would also need brief , easy administer interpret , complement busy clinical practice . It anticipate THINC-it tool free charge downloadable THINC-it website use primary care specialty set . The THINC-it tool accessible via computers/tablets , take 20 minute self-administer clinical setting , performance result immediately available .</brief_summary>
	<brief_title>THINC-it Vortioxetine - Sensitivity Change</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>MDD Population 1 . The participant able willing provide inform consent . 2 . The participant male female 1865 year age . 3 . The participant receive current diagnosis major depressive episode ( MDE ) part MDD per DSM5 criterion . 4 . The participant 's current MDE confirm Mini International Neuropsychiatric Interview ( M.I.N.I 5.0. ) . 5 . The participant outpatient psychiatric setting . 6 . The participant MADRS score â‰¥ 26 screen baseline . 7 . The participant 's report duration current MDE least 3 month . 8 . At least one prior major depressive episode validate previous treatment ( e.g. , guidelineinformed pharmacotherapy and/or manualbased psychotherapy ) . 9 . All participant screen cognitive impairment base DSST performance ( penandpaper version ) maximum baseline score 70 correct symbol enter avoid ceiling effect . 1 . Current alcohol and/or substance use disorder . 2 . Presence comorbid psychiatric disorder MDD focus clinical concern confirm M.I.N.I 5.0 . 3 . Medications approve and/or employ offlabel cognitive dysfunction ( e.g. , psychostimulants ) . 4 . Any medication general medical disorder , opinion investigator , may affect cognitive function ( e.g. , corticosteroid , betablockers ) . 5 . Use benzodiazepine within 12 hour cognitive assessment . 6 . Consumption alcohol within 8 hour cognitive assessment . 7 . Recent use marijuana determine toxicology screen . 8 . Physical , cognitive , language impairment sufficient adversely affect data derive cognitive assessment . 9 . Diagnosis read disability dyslexia . 10 . Clinically significant learn disorder history . 11 . Electroconvulsive therapy ( ECT ) last 6 month . 12 . History moderate severe head trauma ( e.g. , loss consciousness &gt; 1 hour ) , neurological disorder , unstable systemic medical disease opinion investigator likely affect central nervous system . 13 . Pregnant and/or breastfeeding . 14 . Received investigational agent part separate study within 30 day screen visit . 15 . Actively suicidal evaluate suicide risk ( score &gt; 4 MADRS and/or per clinical judgment use ColumbiaSuicide Severity Rating Scale ) . 16 . Currently receive treatment Monoamine Oxidase Inhibitors ( MAOIs ) antidepressant , antibiotic linezolid , intravenous methylene blue . Healthy Control Population 1 . No current past history mental disorder evidence M.I.N.I . 5.0 DSMIV . 2 . No firstdegree relative establish diagnosis healthcare provider mood psychiatric disorder . 3 . No unstable medical disorder . 1 . Use medication general medical disorder and/or condition , opinion investigator , may affect cognitive function ( e.g. , corticosteroid , betablockers ) . 2 . Pregnant and/or breastfeeding . 3 . Consumption alcohol within 8 hour THINCit tool administration . 4 . Recent use marijuana determine toxicology screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>